Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
McKesson
Boehringer Ingelheim
McKinsey

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR MILNACIPRAN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Milnacipran Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00098124 ↗ Study of Milnacipran for the Treatment of Fibromyalgia Completed Forest Laboratories Phase 3 2004-11-01 Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
NCT00225511 ↗ Study Evaluating Effexor XR for Major Depression. Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2004-06-01 Study Evaluating Effexor XR for Major Depression.
NCT00314249 ↗ Study of Milnacipran for the Treatment of Fibromyalgia Completed Cypress Bioscience, Inc. Phase 3 2006-04-01 The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
NCT00314249 ↗ Study of Milnacipran for the Treatment of Fibromyalgia Completed Forest Laboratories Phase 3 2006-04-01 The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Milnacipran Hydrochloride

Condition Name

Condition Name for Milnacipran Hydrochloride
Intervention Trials
Fibromyalgia 20
Depression 7
Primary Fibromyalgia 3
Fibromyalgia Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Milnacipran Hydrochloride
Intervention Trials
Fibromyalgia 28
Myofascial Pain Syndromes 27
Depression 7
Syndrome 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Milnacipran Hydrochloride

Trials by Country

Trials by Country for Milnacipran Hydrochloride
Location Trials
United States 212
Japan 19
Korea, Republic of 5
France 4
Czech Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Milnacipran Hydrochloride
Location Trials
California 12
New York 12
North Carolina 11
Florida 10
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Milnacipran Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Milnacipran Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 14
Phase 2/Phase 3 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Milnacipran Hydrochloride
Clinical Trial Phase Trials
Completed 32
Unknown status 11
Terminated 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Milnacipran Hydrochloride

Sponsor Name

Sponsor Name for Milnacipran Hydrochloride
Sponsor Trials
Forest Laboratories 29
Cypress Bioscience, Inc. 6
Samsung Medical Center 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Milnacipran Hydrochloride
Sponsor Trials
Other 54
Industry 43
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Baxter
Colorcon
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.